Neurogene Inc
NGNE
查看详细走势图
20.010USD
-0.060-0.30%
收盘 12/26, 16:00（美东）报价延迟15分钟
295.65M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-0.30%
5天
-2.63%
1月
-4.67%
6月
+23.82%
今年开始到现在
-12.47%
1年
-12.89%
查看详细走势图
TradingKey Neurogene Inc股票评分
单位: USD 更新时间: 2025-12-26操作建议
Neurogene Inc当前公司基本面数据相对谨慎，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名81/404位。机构持股占比非常高，近一月多位分析师给出公司评级为强力买入。最高目标价59.00。中期看，股价处于上升通道。近一个月，市场表现较差，但技术面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Neurogene Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
6
位分析师
强力买入
评级
59.000
目标均价
+186.55%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Neurogene Inc亮点
亮点风险
Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is in development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.
业绩增长期
公司处于发展阶段，最新年度总收入925.00K美元
利润高增长
公司净利润处于行业前列，最新年度总收入925.00K美元
估值低估
公司最新PE估值-4.87，处于3年历史低位
机构减仓
最新机构持股15.71M股，环比减少17.12%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值665.00
活跃度降低
近期活跃度降低，过去20天平均换手率-0.48
Neurogene Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Neurogene Inc简介
Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is in development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.
公司代码NGNE
公司Neurogene Inc
CEOMcMinn (Rachel L)
网址https://www.neurogene.com/
常见问题
Neurogene Inc(NGNE)的当前股价是多少？
Neurogene Inc(NGNE)的当前股价是 20.010。
Neurogene Inc的股票代码是什么？
Neurogene Inc的股票代码是NGNE。
Neurogene Inc股票的52周最高点是多少？
Neurogene Inc股票的52周最高点是37.266。
Neurogene Inc股票的52周最低点是多少？
Neurogene Inc股票的52周最低点是6.875。
Neurogene Inc的市值是多少？
Neurogene Inc的市值是295.65M。
Neurogene Inc的净利润是多少？
Neurogene Inc的净利润为-75.14M。
现在Neurogene Inc(NGNE)的股票是买入、持有还是卖出？
根据分析师评级，Neurogene Inc(NGNE)的总体评级为--，目标价格为59.000。
Neurogene Inc(NGNE)股票的每股收益（EPS TTM）是多少
Neurogene Inc(NGNE)股票的每股收益（EPS TTM）是-4.106。
相关品种
